Stockwinners Market Radar for May 31, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:49 EDT SPDR Gold Shares holdings rise to 743.21MT from 740.86MT - This is the highest level of holdings since May 2nd.

17:28 EDT United Technologies awarded $3.24B Navy contract modification - United Technologies has been awarded $3.24B for not-to-exceed undefinitized contract modification to a previously awarded advance acquisition contract for the production and delivery of 233 propulsion systems. This modification provides for the production and delivery of 56 F135-PW-100 propulsion systems for the Air Force; 10 F135-PW-100 propulsion systems for the Navy; 24 F135-PW-600 propulsion systems for the Marine Corps; 125 F135-PW-100 and 18 F135-PW-600 propulsion systems for non-Department of Defense, or DoD, participants and foreign military sales, or FMS, customers. Work is expected to be completed in January 2022. FY18 aircraft procurement and FMS funds in the amount of $793.13M will be obligated at time of award, none of which will expire at the end of the fiscal year. This modification combines purchases for the Air Force; Marine Corps; Navy; non-DoD participants and FMS customers. The Naval Air Systems Command is the contracting activity.

17:19 EDT Man Group takes 5.74% passive stake in Ocular Therapeutix - Man Group disclosed a 5.74% stake in Ocular Therapeutix, which represents over 2.45M shares. The filing does not allow for activism.

16:58 EDT Reed's CIO Reed sells 191.6K shars of common stock - In a regulatory filing, Reed's disclosed that its CIO, Christopher Reed, sold 191.6K shares of common stock on May 30th. The total transaction size was $613K.

16:47 EDT Home Depot director Roseborough sells 8.5K shares of common stock - In a regulatory filing, Home Depot disclosed that its General Counsel, Teresa Roseborough, sold 8.5K shares of common stock on May 28th. The total transaction size was $1.65M.

16:31 EDT O'Reilly Automotive announces additional $1B stock buyback authorization - O'Reilly Automotive announced that its board approved a resolution to increase the authorization amount under its share repurchase program by an additional $1B, raising the aggregate authorization under the program to $12.75B. The additional $1B authorization is effective for a three-year period, beginning on May 31, 2019.

16:13 EDT Halcon Resources receives noncompliance notice from NYSE - Halcon Resources disclosed that it received notice from the New York Stock Exchange, or NYSE, that the average price of its common stock has fallen below the NYSE's continued listing standard which requires that the average closing price of a listed company's common stock not be less than $1.00 per share for a period of 30 consecutive trading days. Under NYSE rules, the company will regain compliance if, during the six month period following receipt of the NYSE notice and on the last trading day of any calendar month, Halcon's common stock price per share and 30 trading-day average share price is at least $1.00. During this period, the company's common stock will continue to be traded on the NYSE, subject to compliance with other NYSE listing requirements. Halcon intends to notify the NYSE of its intent to cure this deficiency, to the extent it becomes necessary.

16:06 EDT Digirad Corp announces 1-for-10 reverse stock split - Digirad announced a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 and that it had filed a certificate of amendment of the company's restated certificate of incorporation in order to effect the reverse split. The reverse split will be effective after the market closes on June 4. Beginning with the opening of trading on June 5, the company's common stock will continue to trade on Nasdaq under the same symbol, but will trade on a split-adjusted basis under a new CUSIP number. The certificate of amendment will also, upon effectiveness on June 4, reduce the number of authorized shares of common stock under the company's restated certificate of incorporation to 30M shares authorized. The stockholders of the company approved the reverse split and the share reduction at the company's annual meeting of stockholders held on May 1. In connection with approving the reverse split, the company's stockholders granted authority to the board of Digirad to determine, at its discretion, a ratio within the range of 1-for-5 to 1-for-10, at which to effectuate the reverse split. The reverse split was approved by the board on March 8 and the ratio of 1-for-10 was approved by the board on May 15. The reverse split is expected to enable the company to meet the Nasdaq listing rule that requires a minimum closing bid price of $1.00 per share of the company's common stock in order to continue the listing of the common stock on Nasdaq. As a result of the Reverse Split, every 10 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders and with no change in the par value per share of $0.0001. The Reverse Split will proportionately reduce the number of shares of common stock available for issuance under the Company's equity incentive plans and proportionately reduce the number of shares of common stock issuable upon the exercise of stock options and upon the release of restricted stock units outstanding immediately prior to the effectiveness of the Reverse Split. The Reverse Split reduces the number of shares of the Company's outstanding common stock from approximately 20.3 million pre-Reverse Split shares to approximately 2.0 million post-Reverse Split shares. No fractional shares will be issued as a result of the Reverse Split. Owners of fractional shares outstanding after the Reverse Split will receive one full share of post-Reverse Split shares.

16:06 EDT Emerge Energy trading resumes

14:47 EDT Donaldson increases divudend 10.5%, authorizes new share repurchase plan - Donaldson Company announced that its board approved an increase to its quarterly cash dividend and authorized a new share repurchase program. Donaldson's board declared a regular cash dividend of 21c per share, an increase of 10.5% from the prior quarterly cash dividend of 19c per share. The dividend is payable June 28 to shareholders of record on June 13. Additionally, Donaldson's board authorized the repurchase of up to 13M shares of its common stock, or approximately 10% of its outstanding shares. The new repurchase authorization replaces the existing authority that was approved in May 2015. To date, the company has repurchased 11.6M shares under the prior authorization of 14M shares.

14:30 EDT Vislink regains full Nasdaq compliance - Vislink Technologies announced that It has received notice from The Nasdaq Stock Market on May 29 indicating that the company has regained full compliance with all applicable listing requirements of the Nasdaq Capital Market. Accordingly, The company's stock will continue to be listed and trade on the Nasdaq Capital market, and Nasdaq considers the matter closed.

14:21 EDT DelMar Pharmaceuticals shares jump after update on ASCO presentations - Shares of the small-cap drugmaker's stock are up 93c, or 55%, to $2.62 following the disclosure in a filing of updates presented at the American Society of Clinical Oncology, or ASCO, annual meeting.

14:16 EDT DelMar Pharmaceuticals announces clinical updates presented at ASCO - In a regulatory filing, DelMar Pharmaceuticals reported that the company presented clinical updates on May 31 from the company's ongoing first- and second-line trials in patients with MGMT-unmethylated glioblastoma multiforme at a key opinion leader presentation during the 2019 American Society of Clinical Oncology, or ASCO, annual meeting. At the KOL presentation, the company provided an update on the ongoing Phase 2 clinical study investigating the front line treatment of VAL-083 with radiation therapy in newly diagnosed MGMT-unmethylated GBM. As of May 17, eighteen patients have been enrolled in the trial. Of these patients, fifteen have received their post-cycle 3 MRI and investigator assessment, and ten have received their post-cycle 7 MRI and investigator assessment. Two patients have not been on the study long enough to reach their first assessment, and one patient died before their first assessment. Assessments are based on the trial investigator's clinical and radiologic assessment, according to the Response Assessment in NeuroOncology criteria. For the fifteen patients who have received at least one assessment, eight patients were assessed with a best response of "Complete Response" and seven patients were assessed with a best response of "Stable Disease". Fourteen of the eighteen patients were still alive at the data cut-off date. The company also provided an update on the ongoing second-line Phase 2 clinical study of VAL-083 in patients with MGMT-unmethylated, Bevacizumab-naive recurrent GBM. As of May 5, 51 patients have been enrolled, 35 patients at a starting dose of 40 mg/m2, and 16 patients at a starting dose of 30 mg/m2. For the 47 patients who have been on study long enough to be assessed at the post-cycle 2 MRI: 9/35 patients initially receiving 40 mg/m2 exhibited "Stable Disease" per investigator assessment at the end of cycle 2; 4/12 patients initially receiving 30 mg/m2 exhibited "Stable Disease" per investigator assessment at the end of cycle 2. Additionally, the study protocol has been amended to include enrollment of up to 24 newly-diagnosed GBM patients who have completed chemoradiation treatment with TMZ and received no subsequent TMZ maintenance therapy but will receive VAL-083 instead. This Group has been included to explore whether earlier intervention with VAL-083 instead of TMZ maintenance therapy offers clinical benefit and extends the time to recurrence as compared to TMZ maintenance therapy. Consistent with prior studies, myelosuppression is the most common adverse event in both ongoing clinical trials, the company stated in the filing.

12:01 EDT Slack Technologies says has over 10M daily active users - In a filing, Slack Technologies said that during the three months ended January 31, Slack's daily active users exceeded 10M. As of January 31, Slack had more than 600,000 organizations with three or more users, comprised of more than 500,000 organizations on its free subscription plan, and more than 88,000 paid customers, including more than 65 companies in the Fortune 100. As of April 30, Slack had more than 95,000 paid customers. Slack's direct sales and customer success efforts are "focused on larger organizations who have a greater number of users and teams and have the potential to increase spend over time." Slack measures the number of paid customers greater than $100,000 of annual recurring revenue, or ARR, as a gauge of adoption within and expansion into large enterprises. As of January 31, Slack had 575 paid customers greater than$100,000 of ARR, which accounted for approximately 40% of its revenue in FY19 . As of April 30, Slack had 645 paid customers greater than$100,000 of ARR, which accounted for approximately 43% of its revenue in the three months ended April 30. Slack generates revenue primarily from the sale of subscriptions for Slack. Paid customers typically pay on a monthly or annual basis, based on the number of users that they have on Slack.

10:41 EDT Amazon acquires Sizmek Ad Server and Sizmek DCO - Amazon.com announced that it has signed an agreement to acquire Sizmek Ad Server and Sizmek Dynamic Creative Optimization. "Sizmek and Amazon Advertising have many mutual customers, so we know how valued these proven solutions are to their customer base. Sizmek has been searching for a buyer for Sizmek Ad Server and Sizmek DCO, and we are both committed to continuing serving their customers at the high standards they've come to expect," the company said in a blog post. Once the deal closes, Sizmek Ad Server and Sizmek DCO will operate separately from Amazon Advertising "for the time being," Amazon added. Reference Link

10:26 EDT Constellation Pharmaceuticals Inc trading halted, volatility trading pause

10:19 EDT Hemispherx stockholders approve 1-for-44 reverse stock split - Hemispherx Biopharma announced that its stockholders voted in favor to grant the Board of Directors the authority to effect a reverse stock split of the company's issued and outstanding shares of Common Stock. The proposal passed by approximately 55% of all issued and outstanding shares and approximately 86% of the shares actually voted were voted in favor of the reverse split. Following the stockholder vote, the Board met and approved a 1-for-44 reverse stock split to achieve a value of approximately $5 per share. The Company anticipates that the reverse stock split will be effective on June 10, 2019, and the Company's common stock will begin trading on a split-adjusted basis on June 11, 2019.

10:14 EDT Genocea surges after selection as top 10 featured ASCO immuno-oncology abstract - Genocea Biosciences shares are surging higher after the biopharmaceutical company announced earlier that the Journal of Clinical Oncology, an American Society of Clinical Oncology Journal, has selected the company's GEN-009 clinical results presentation at the 2019 ASCO Annual Meeting as a top 10 featured abstract in immuno-oncology. The full poster will be available on the Genocea website here concurrent with its presentation tomorrow, the company noted. In early trading, Genocea shares are up $2.90, or 64.4%, to $7.40. Reference Link

10:00 EDT Gap falls -15.7% - Gap is down -15.7%, or -$3.23 to $17.37.

10:00 EDT Capital Senior Living rises 10.8% - Capital Senior Living is up 10.8%, or 39c to $3.99.

10:00 EDT Genesco rises 17.4% - Genesco is up 17.4%, or $7.03 to $47.28.

09:30 EDT Mack-Cali holder Bow Street says ISS recommends vote FOR Bow Street nominees - Bow Street, a New York-based investment firm that beneficially owns approximately 4.5% of the outstanding shares of common stock of Mack-Cali Realty, announced that Institutional Shareholder Services, or ISS, has recommended that Mack-Cali shareholders vote the GOLD proxy card "FOR" the election of Bow Street's "highly-qualified," independent director nominees MaryAnne Gilmartin, Nori Gerardo Lietz, and Alan Batkin in connection with Mack-Cali's Annual Meeting of Shareholders to be held June 12.

09:08 EDT Magellan Midstream, Navigator Energy extend open season for Voyager pipeline - Magellan Midstream Partners and Navigator Energy Services announced an extension of the open season to solicit commitments from shippers for the proposed Voyager Pipeline to transport crude oil from Cushing, Oklahoma and Midland, Texas to Houston. Binding commitments are now due by 12:00 p.m. Central Daylight Time on Aug. 30, 2019. The level of shipper interest in the Midland origin, announced in March, combined with shipper requests for additional grades of crude oil and condensate at Cushing, requires further evaluation of the scope of the Voyager Pipeline project. As currently contemplated, the proposed Voyager Pipeline would include construction of 20-inch diameter pipelines from both Magellan's Cushing and Midland terminals to Magellan's terminal in Frost, Texas. From Frost, a 24-inch diameter pipeline would be constructed to Magellan's terminal in East Houston. As proposed, the Voyager Pipeline is expected to have an initial capacity of up to 400,000 barrels per day, with the ability to expand if warranted by industry demand. Subject to receipt of sufficient customer commitments and all necessary permits and approvals, the pipeline is expected to be operational in early 2021.

08:55 EDT BRF S.A. reports negotiations with Marfrig on potential business combination - In a regulatory filing, BRF S.A. informed its shareholders and the market, "in the context of the assessment of strategic options that may generate value for its shareholders," that it has started negotiations with Marfrig S.A. in connection with a potential business combination between the two companies. The company's board approved the execution of a binding Memorandum of Understandings between Marfrig and the company setting forth rules and conditions regarding the access to information that provides for an exclusivity period of ninety days, renewable for additional thirty days, during which neither party may begin negotiations with third parties. "In the context of such analysis, the company and Marfrig shall evaluate, with their respective legal, accounting and financial advisors, the economic benefits that may result from the eventual implementation of the Transaction, as well as the most efficient corporate structure to be adopted," the filing stated. "Pursuant to the Memorandum of Understandings, the valuation of any combination will be based on the average of the daily weighted price quotation of the shares of each company in the last forty five calendar days in B3 S.A. - Brasil, Bolsa, Balcao immediately prior to the date of disclosure of this Material Fact, that is, between April 15 and May 29, inclusive, which would result in an equity ownership by the shareholders of the company of 84.98% and by the shareholders of Marfrig of 15.02%. The company clarifies, however, that the companies will conduct a reciprocal due diligence process during the exclusivity period, which results may, at the joint discretion of both companies, cause the terms of the Transaction to be adjusted," the filing added.

08:41 EDT Turning Point Therapeutics announces updated interim TRIDENT-1 data - Turning Point Therapeutics announced updated interim data from its ongoing Phase 1/2 TRIDENT-1 clinical study of lead drug candidate repotrectinib in ROS1-positive non-small cell lung cancer, or NSCLC, patients. The results, which will be presented today during an oral session at the annual meeting of the American Society of Clinical Oncology, or ASCO, demonstrate ongoing antitumor activity and a manageable safety profile across multiple dose cohorts in both tyrosine kinase inhibitor, or TKI, naive and TKI-pretreated patients, including patients with intracranial disease. Repotrectinib is an investigational next-generation TKI designed to effectively target ROS1 and TRK A/B/C and systemically overcome resistant mutations that invariably result following treatment with other TKIs. ROS1 rearrangement is an oncogenic driver of tumors in up to 2.6 percent of U.S. advanced NSCLC patients. A total of 83 patients were treated with repotrectinib at dose levels from 40 mg daily to 200 mg twice daily. Repotrectinib was generally well tolerated, with the most frequent treatment emergent adverse events, or TEAEs, being Grade 1 or 2. The TEAEs found in greater than 25% of pts were dizziness, dysgeusia, dyspnea, fatigue, constipation, paresthesia and anemia. There were few Grade 3 treatment-related AEs; dizziness, and dyspnea, hypophosphatemia, hypoxia, pleural effusion, and weight increase and no Grade 4 treatment-related AEs or cases of dizziness leading to treatment discontinuation. No additional dose-limiting toxicities, or DLTs, have occurred since the last data cut-off of Oct. 31, 2018. Prior DLTs included Grade 3 dyspnea/hypoxia and Grade 2 and Grade 3 dizziness. Four total Grade 5 TEAEs have occurred, with one Grade 5 case of respiratory failure reported as related to disease progression since the last interim data update. Within the ROS1+ NSCLC blinded independent central review, or BICR, efficacy evaluable population, the median number of prior TKI therapies was one, the majority of which were crizotinib. Forty-five percent of patients remained on treatment, with 12 of the 15 patients remaining on treatment for more than 12 months. In TKI-naive patients, overall response rate, or ORR, by BICR was 82%. At a dose of 160 mg QD or above, the likely recommended Phase 2 dose, ORR by BICR remains at 83%, consistent with the prior update. In TKI-pretreated patients, ORR by BICR improved from 28% in the prior data cut-off to 32%, and from 44% to 55% in patients pretreated with 1 TKI and dosed at 160 mg QD or above. Five patients pretreated with crizotinib had a ROS1 G2032R solvent front mutation detected at baseline by plasma cfDNA or next-generation sequencing tests. All five patients had tumor regressions, including two confirmed partial responses at the 160 mg QD dose level.

08:35 EDT Ideanomics enters into JV with iUnicorn to expand EV activities - Ideanomics announced the signing of a strategic joint venture with China's iUnicorn. iUnicorn is a Chinese ride-hailing service which offers only luxury branded electric vehicles in addition to Chinese electric vehicle manufactures. The JV will become a green finance and integrated marketing service enterprise for new energy vehicles as part of Ideanomics' New Energy Vehicle division. The JV will become the exclusive sales, marketing, operations, and financing partner for iUnicorns activities, as well as for other EV activities, including tour bus and other specialty vehicles. Ideanomics will have 50.1% ownership control. The board will contain 5 members comprised of 3 from Ideanomics, including the chairman, and 2 from iUnicorn. Additionally, iUnicorn will appoint the CEO and the parties will coordinate on the appointment of the JV's CFO. The JV will be domiciled outside of China to allow the flexibility to spin-off the business in the future. Ideanomics will contribute advisory and sales responsibilities which will include arranging ABS-based auto financing with its bank and financing partners, from assets provided by vehicle manufacturers to the value of RMB5B, as well as order origination in Vietnam, and other target territories up to and including the U.S. Ideanomics will also contribute its tour bus and commercial vehicle orders. iUnicorn will contribute its signed sales orders in Chengdu of 19,000 vehicles, plus a further 89,000 vehicle orders mainly in Sichuan province, which are in addition to the Chengdu order. iUnicorn will also provide sales and operational support for the joint venture. The fulfillment of these orders will commence immediately, with the Chengdu order anticipated to begin to take delivery during the 3rd quarter of 2019. The JV will generate revenues from fees from ABS, ranging from 0.7% to 1.5% and also commissions on vehicle sales orders, which will vary according to manufacturer and vehicle model.

08:34 EDT Wayside Technology CEO Steve DeWindt resigns, Michael Vesey named interim CEO - Wayside Technology announced that Steve DeWindt has resigned as the company's president, CEO and member of the board of the company, effective June 6, for personal health reasons. As a result, he will not stand for re-election as a director at the company's annual meeting of stockholders. Michael Vesey, the company's current VP and CFO, will serve as the company's interim president and CEO until a permanent successor has been named. Vesey has served as the company's VP and CFO since October 2016.

08:32 EDT Canadian Pacific, Yang Ming sign long-term agreement for North America - Canadian Pacific Railway and Yang Ming Marine Transport Corporation announced a three-year agreement to safely and efficiently connect Yang Ming customers with North America, via the Port of Vancouver. Effective January 1, 2020, CP will handle all of Yang Ming's Vancouver traffic. The agreement also provides synergies across THE Alliance, as Hapag-Lloyd, Ocean Network Express and Yang Ming will now be moving, in whole or in part, on CP out of Canada's largest and most important ocean terminal, Global Container Terminal's Deltaport.

08:18 EDT Vereit closes on $407M institutional partnership with KIS - VEREIT announced it has closed on the previously reported institutional partnership which includes six assets totaling approximately $407M and 4.8 million square feet of industrial assets with investment grade tenants. These assets make up the initial portfolio of a new Korea Investment & Securities Co. industrial fund which will be advised by Ocean West Capital Partners. The stakeholders have agreed to a traditional 80/20 equity structure. The portfolio of industrial assets is currently 100% leased and located across five different states. The investment was made at a capitalization rate just under 6.0%. As part of the agreement, VEREIT's in-house infrastructure of acquisitions, property management, legal, leasing and asset management teams will work to maximize each asset to increase value for the portfolio.

08:05 EDT ContraVir Pharmaceuticals announces 1-for-70 reverse stock split - ContraVir Pharmaceuticals announced a reverse split of its common stock, $0.0001 par value, at a ratio of 1-for-70 effective May 31. The company's common stock will begin trading on a split-adjusted basis when the markets open on June 3 under the existing trading symbol. The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on Nasdaq. As a result of the reverse split, each seventy pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 41.3M shares to approximately 590,500 shares. Proportionate adjustments will be made to the conversion and exercise prices of the company's outstanding warrants, stock options and to the number of shares issued and issuable under the company's equity incentive plans. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the par value of the common stock. On March 11 the board of directors of the company approved the reverse stock split, subject to shareholder approval. On May 2, a majority of the company's shareholders approved giving the board discretionary authority to enact the reverse stock split. The Board approved the reverse stock split on a one for seventy ratio on May 9.

08:02 EDT Basic Energy announces $5M share repurchase program - Basic Energy Services announced that its Board of Directors has authorized the repurchase of up to $5M of its outstanding shares of common stock from time to time in open market or private transactions, at the company's discretion. This authorization expires on June 4, 2020. The timing and actual number of shares repurchased will depend on a variety of factors including the stock price, corporate and regulatory requirements and other market and economic conditions. The stock repurchase program may be suspended or discontinued as determined by the Board of Directors. CEO T. M. "Roe" Patterson said, "The Board's authorization and our implementation of a stock repurchase program reflects our confidence in the long-term value of Basic's market position and financial performance, which have been severely discounted due to current conditions in financial markets. We expect the stock repurchase program to be effected without drawing on our existing ABL credit facility, and we expect our year-end cash balance to be approximately $55 - $60 million and total liquidity of approximately $130 - $135 million in the event we fully utilize the current repurchase authorization by December 31, 2019."

07:34 EDT Invitae to present research on germline multigene panel testing at ASCO meeting - Researchers from Invitae will present data that underscore the clinical utility of comprehensive genetic information for patients with breast, colorectal, prostate and pancreatic cancer to inform treatment decisions. Among the data, researchers will discuss findings showing that multigene germline genetic testing for breast cancer patients impacts patient outcomes and informs surgical strategy, precision medicine treatment and clinical trial eligibility. The studies will be presented at the American Society for Clinical Oncology Annual Meeting. A study of breast cancer patients conducted with researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians, evaluated germline genetic testing for 912 breast cancer patients, approximately half of whom met widely accepted clinical guidelines for testing and half of whom did not. Pathogenic/likely pathogenic germline variants were found in 8.65% of patients. Among patients with P/LP germline variants, 85% had variants in cancer-risk genes with established management recommendations and 80% had variants that made them eligible for clinical trials and/or precision medicine-based cancer treatments, such as PARP inhibitors. In 62% of patients with P/LP germline mutations, their clinicians reported the findings impacted their patients' outcomes. Another study presented at the meeting examined testing in colorectal cancer using multigene panels, and suggests one in five patients referred for genetic testing have clinically actionable germline variants, nearly half of which remain undetected when only a narrowly defined panel of the five mismatch repair genes are tested. Furthermore, some of these variants were in genes associated with known precision therapeutic implications or clinical trial eligibility, as well as established clinical management guidelines.Germline testing was performed on 9,000 patients with colorectal cancer and clinically significant variants were identified in 21% of patients. When only a limited genetic panel was used, 9% of patients had a pathogenic finding, which increased to 15% when 19 guidelines-based colorectal cancer genes were assessed. Using a comprehensive multigene panel, P/LP variants in genes with known precision therapy implications were detected in 14% of patients, and 17% had P/LP variants associated with established clinical management guidelines. These data add to the evidence supporting the value of comprehensive germline genetic testing for colorectal cancer patients to identify candidates for precision medical treatments and provide clinical guidance to at-risk family members.

07:13 EDT Hill International, Aecom joint venture to provide project management for NYCDDC - Hill International (HIL) announced that New York City Department of Design and Construction, or NYCDDC selected a joint venture of Aecom (ACM) and Hill to provide program and project management for New York City's borough-based jails program. This multi-billion dollar program features constructing four new jails in the boroughs of Manhattan, Brooklyn, Queens and the Bronx to allow for the city to close its main jail on Rikers Island. DDC and Aecom-Hill will manage the design-build construction of the four new facilities. The Aecom-Hill program management services include creating procedures, protocols, forms and program and project manuals for all aspects of the program; developing procurement strategies and protocols and creating program- and project-specific virtual document and payment control systems. In addition, the JV will prepare and manage industry outreach strategies; prepare specifications and criteria for each design-build project; and monitor the design-build teams' M/WBE requirements. The JV will also manage the four jail projects until closeout and provide quality assurance/quality control services.

07:09 EDT Iovance Biotherapeutics announces updated data from LN-145 study - Iovance Biotherapeutics announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma. At 7.4-month median follow-up in the ongoing study of LN-145 in advanced cervical cancer, an 11% complete response rate, or CR, was seen. Furthermore, the median duration of response had not been reached. At 8.8-month median follow-up in the ongoing study of lifileucel in advanced melanoma, median duration of response had not been reached. Updated data from the ongoing innovaTIL-04 and innovaTIL-01 studies will be presented at the American Society of Clinical Oncology, or ASCO. As of May 14, data from the innovaTIL-04 study in 27 patients with recurrent, metastatic or persistent cervical cancer demonstrated an objective response rate of 44% and a disease control rate of 85%. At 7.4-month median follow-up, 10 patients maintained a response and the median DOR had not been reached. The mean patient age was 45 years and study participants had experienced a mean of 2.4 prior lines of therapy. As of May 8, results from Cohort 2 in the ongoing innovaTIL-01 study demonstrated an ORR of 38% in 66 consecutively dosed post-PD-1 patients with Stage IIIC/IV unresectable melanoma. In this study, patients had experienced a mean of 3.3 lines of prior therapy including anti-PD1 blocking antibody, and the patients had a high baseline tumor burden. The disease control rate was 80%. At 8.8-month median follow-up, median DOR had not been reached.

07:06 EDT Alnylam doses first patient in Phase 1 study of ALN-AGT - Alnylam Pharmaceuticals announced that the first patient has been dosed in the Company's Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen, or AGT, for the treatment of hypertension in high unmet need populations, including patients with resistant or refractory hypertension, chronic kidney disease or heart failure. The company expects to report initial results in late 2019.

07:05 EDT Brazil Minerals announces first iron project, technology partnership development - Brazil Minerals announced that it has obtained the rights to an iron project area with 4,120 acres in the Iron Quadrangle, one of the iron regions with multiple operating mines. Iron ore is in demand with sales of Brazilian iron ore for export or for use by local steelmakers. Recently, the price of iron delivered at a foreign port spiked to $109 per ton. Brazil Minerals' claim holds potential for several reasons, including its location in proximity to one of the initial iron mines from Vale. The local geology shows possible secondary deposits, i.e., occurrences of eluvial/colluvial iron mineralization with potential for lump ore production. This type of product is aimed at the domestic market and, in general, presents a combination of low production cost and relatively high margins, when compared with iron production for export. As part of the agreement in which Brazil Minerals was advised, at no initial cost, regarding this iron opportunity by a local private enterprise, the company will evaluate technology solutions initially developed by this enterprise which are aimed at minimizing the environmental disturbances of an iron mine. These solutions center on processing without water and enabling smaller scale operations to increase profitability and product quality. Refinements may be co-developed during this technology partnership. As soon as it is feasible, Brazil Minerals plans to proceed with geological studies of the area to ascertain various aspects of the mineral right, including quantification of mineralization and reserve potential.

07:04 EDT Merck says KEYTRUDA demonstrates improves OS at final analysis of KEYNOTE-048 - Merck announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy and in combination with chemotherapy, for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma, or HNSCC, at the 2019 American Society of Clinical Oncology Annual Meeting. Data include the first-time presentation of certain overall survival, or OS, hypotheses from the KEYTRUDA in combination with chemotherapy study arm based on PD-L1 expression and the KEYTRUDA monotherapy study arm in the total patient population. Results of an interim analysis were presented at the European Society for Medical Oncology 2018 Congress and demonstrated superior OS outcomes for KEYTRUDA in combination with chemotherapy in the total population and KEYTRUDA monotherapy in patients whose tumors expressed PD-L1 with Combined Positive Score, or CPS, greater than or equal to20 and CPS greater than or equal to 1 compared with the EXTREME regimen, the current standard of care. The new findings presented today from the final analysis showed that KEYTRUDA in combination with chemotherapy reduced the risk of death by 40% in patients whose tumors expressed PD-L1 with CPS greater than or equal to 20, demonstrating significantly longer OS compared with the EXTREME regimen, the current standard of care. For the dual primary endpoint of progression-free survival, or PFS, statistical significance was not achieved for KEYTRUDA in combination with chemotherapy in the CPS greater than or equal to20 population compared with the EXTREME regimen. New findings for the CPS greater than or equal to 1 population showed KEYTRUDA in combination with chemotherapy reduced the risk of death by 35% in these patients, with significantly longer OS compared with the EXTREME regimen. Per the sequential testing strategy, superiority for PFS was not tested in this population. Results for OS with KEYTRUDA monotherapy in the total population were consistent with the previously presented interim analysis, where non-inferiority was demonstrated, with a median OS of 11.5 months for KEYTRUDA monotherapy in the total population compared with 10.7 months for the EXTREME regimen. There was no difference in PFS between KEYTRUDA monotherapy in the total population and the EXTREME regimen.

06:46 EDT Sempra Energy announces Cameron LNG ships first cargo of LNG from export project - Sempra LNG, a subsidiary of Sempra Energy, announced that Cameron LNG has shipped the first commissioning cargo of liquefied natural gas, or LNG, from the first liquefaction train of the export project in Hackberry, Louisiana. Commissioning cargos are a step in the start-up process and support stabilizing production and performance testing. Commercial operations from the facility will begin after Cameron LNG receives authorization from the Federal Energy Regulatory Commission, which is expected in mid-2019. Phase 1 of the Cameron LNG export project includes the first three liquefaction trains that will enable the export of approximately 12M tonnes per annum of LNG, or approximately 1.7B cubic feet per day.

06:40 EDT LyondellBasell raises quarterly dividend to $1.05 - LyondellBasell announced that its board has declared a quarterly dividend of $1.05 per share, representing a 5% increase over the company's Q1 dividend. The dividend will be paid June 17 to shareholders of record June 10, with an ex-dividend date of June 7.

06:20 EDT Centene announces addition of WellCare CEO, CFO to executive leadership team - Centene (CNC) announced that upon completion of the pending combination with WellCare (WCG), Ken Burdick, currently CEO of WellCare, and Drew Asher, currently executive VP and CFO of WellCare, will join Centene in executive leadership positions. Burdick and Asher will report directly to Michael Neidorff, chairman, president and CEO of Centene. Burdick's employment agreement is for a two-year term. Centene expects to announce additional details on the combined company's organizational structure and leadership team at its previously scheduled investor day to be held on June 14. As previously announced, Centene and WellCare agreed to combine in a transaction that will create a healthcare enterprise focused on government-sponsored healthcare programs. The combination, which is expected to close by the first half of 2020, remains subject to approval by Centene and WellCare shareholders and other customary closing conditions.

06:16 EDT Conn's announces changes to leadership team - Conn's (CONN) announced changes to its leadership team to support retail opportunity. Lee Wright has been named executive VP and COO. In this new role, Wright will be responsible for leading key activities within the company's retail and credit operations. Wright joined Conn's in June 2016 as the company's CFO. Prior to joining the company, Wright served as CEO of Professional Directional Enterprises, an energy services company, since 2015 and served as its president from 2012 into 2015. George Bchara has been promoted to CFO. Bchara joined Conn's as VP and CAO in December 2016. Prior to joining the company, he served as senior VP and CAO of BankUnited, based in Miami Lakes, Florida, from March 2013 to December 2016. Ryan Nelson has been promoted to VP and CAO. Nelson joined Conn's as VP and controller in May 2018. Prior to joining Conn's, Nelson spent seven years with EnLink Midstream Partners (ENLK), a midstream energy services company, where he worked in several leadership roles.

06:09 EDT Tesla: Model 3 available to order in Australia, Hong Kong, Japan, Ireland, Macau - Tesla said via Twitter: "We *do not* want to alarm anyone, but Model 3 is now available to order in Australia, Hong Kong, Japan, New Zealand, Ireland and Macau at Tesla.com." Reference Link

06:07 EDT Conn's sees Q2 SSS down 4% to flat

05:39 EDT Cummins, Isuzu enter into power-source partnership agreement - Cummins and Isuzu Motors announced an expansion in their partnership by entering into the Isuzu Cummins Powertrain Partnership agreement. "The agreement formalizes a business structure for the two companies to evaluate and carry out opportunities to jointly develop and bring new diesel and diesel-based powertrains to global markets. Through this Powertrain Partnership, Isuzu and Cummins share the commitment to leverage both companies' technical strengths to develop market-leading architectures for customers around the world. Cummins and Isuzu committed to form an alliance board and to assign a team of dedicated individuals from each company to continue exploration of potential opportunities in product technology development, procurement and manufacturing."